Decisions surrounding pediatric extracorporeal membrane oxygenation (ECMO) use are complex and nuanced. Medicine continues to push the envelope with increasing use in high-risk populations, and patient conditions previously considered "absolute" contraindications (1-3). As a result, ECMO has saved numerous children's lives, and restrictions on ECMO provision have eased. Concurrently, indiscriminate use of this resource-intensive, high-morbidity, and mortality therapy must be avoided. It is imperative that we proceed cautiously in the absence of high-quality evidence. Medical practice and ECMO decision-making in particular involve clinical judgment, fulfillment of fiduciary obligations, goal concordant care, and professional stewardship all while ensuring benefit to patients (4).Vital for informed decision-making is an understanding of patient cohorts at increased risk of adverse outcomes, and neurologic complications are a welldescribed, major cause of patient morbidity (5). Simultaneously, many intensivists consider baseline neurologic comorbidity when determining ECMO candidacy (2,6). A 2015 survey of ECMO program directors revealed dramatic variability among experts in determining appropriateness for ECMO (6); 38% of respondents would not offer ECMO to an adolescent with cerebral palsy, severe developmental delay and scoliosis, with acute respiratory failure. Although some variability is expected, this degree of subjectivity for how neurologic comorbidities influence decisions indicates susceptibility to bias. Ideally, such high stake decisions should be grounded in high-quality evidence (6). Unfortunately, this wide-ranging variability remains a challenge. Gathering prospective data to examine outcomes of ECMO in patients with neurologic comorbidities is unlikely given heterogeneity, frequency, and expected lack of equipoise for randomized controlled trials.In this context, the article by Dante et al (7) in this issue of Pediatric Critical Care Medicine provides valuable data around outcomes in patients with preexisting neurologic "disorders" or "neurofunctional disability" supported on ECMO. "Disability" criteria were adjudicated by baseline Pediatric Cerebral Performance Category (PCPC) or Pediatric Overall Performance Category (POPC). Of the study population, 70 (11.8%) had a baseline PCPC score 3-5, and 189 (31.9%) had a POPC score of 3-5. Notably, the ECMO cohort included 34 patients (5.7%) with a PCPC/POPC score of 4 or 5 indicating severe disability (dependence on others for activities of daily life) or vegetative state (8). Many